Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
1
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence- based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
Abstract
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence- based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
참고문헌 (27)
- 송후림, "Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study", Clinical Psychopharmacology and Neuroscience, 13(2), pp.144~149 (2015), 대한정신약물학회
- Citrome L, "Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed", J Affect Disord, 196, pp.225~233 (2016)
- McCormack PL, "Vilazodone : a review in major depressive disorder in adults", Drugs, 75, pp.1915~1923 (2015)
- Laoutidis ZG, "Desvenlafaxine for the acute treatment of depression : a systematic review and metaanalysis", Pharmacopsychiatry, 48, pp.187~199 (2015)
- Zadka Ł, "Levomilnacipran—a successor of milnacipran with a higher noradrenergic selectivity", Acta Pol Pharm, 73, pp.285~289 (2016)
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- Vieta E, "Therapeutic options in treatmentresistant depression", Ann Med, 43, pp.512~530 (2011)
- Sueki A, "Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?", Neuropsychiatr Dis Treat, 12, pp.1269~1273 (2016)
- Shim IH, "Prevalence rates and clinical implications of bipolar disorder"with mixed features"as defined by DSM-5", J Affect Disord, 173, pp.120~125 (2015)
- Wang HR, "Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials", Int J Neuropsychopharmacol, 18, pp.pyv023~ (2015)
- 우영섭, "Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients", Clinical Psychopharmacology and Neuroscience, 14(1), pp.1~16 (2016), 대한정신약물학회
- 석정호, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅱ) : 정신병적 양상을 동반하지 않은 주요우울장애의 약물치료", 신경정신의학, 46(5), pp.461~468 (2007), 대한신경정신의학회
- Seok Seo J, "The Korean Medication Algorithm for Depressive Disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
- National Collaborating Centre for Mental Health, "Depression: the treatment and management of depression in adults" (2010), British Psychological Society
- "Treatment of patients with major depression and practical guideline" (2010)[URL]
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder:section 3. pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
- Bauer M, "Task force on unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)
- 왕희령, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", PSYCHIATRY INVESTIGATION, 11(1), pp.1~11 (2014), 대한신경정신의학회
- Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015", World J Biol Psychiatry, 16, pp.76~95 (2015)
- Malhi GS, "Royal australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction", J Affect Disord, 117(Suppl 1), pp.S1~S1 (2009)
- MacQueen GM, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section6. special populations: youth, women, and the elderly", Can J Psychiatry, 61, pp.588~603 (2016)
- Suehs B, "Texas medication algorithm project procedural manual major depressive disorder algorithms" (2008), Texas Department of State Health Services
- Bauer M, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders in primary care", World J Biol Psychiatry, 8, pp.67~104 (2007)
- Wang HR, "Korean medication algorithm for depressive disorder 2017" (2017), ML Communication
- Edwards SJ, "Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression : a systematic review and economic evaluation", Health Technol Assess, 17, pp.1~190 (2013)
- Dickstein DP, "Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation", J Child Adolesc Psychopharmacol, 19, pp.61~73 (2009)